الفهرس Only 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Early damaging events of inflammation in pathogenesis of stroke -where a short time window- allow us to search for therapeutic agents to be used for primary prevention of stroke through anti inflammatory effect in those with high risk factors. Post ischemic inflammation is a dynamic process, which evolves within a much longer time frame (hours to several days), providing a potentially longer therapeutic window. In addition, the identification of the major molecular elements that trigger and promulgate inflammatory signals indicates that some of them may be important therapeutic targets.
1-Using inflammatory markers and recent anti inflammatory therapy in future studies support the efficiency of anti inflammatory therapy if followed up by inflammatory markers.
2-Studies are required to compare between traditional therapy and recent approach of anti inflammatory as regard outcome of stroke.
3-Further studies are required to find the best preventive anti inflammatory therapy for every risk factor and the best inflammatory markers to follow up.
4-Practical recommendations:
A. Early intervention through determine patients with risk factors for stroke and those having inflammatory markers of risk of stroke incidence and giving therapeutic agents with anti inflammatory effect to decrease risk of stroke used for neuroprotection and prevention of first stroke occurrence. These agents used as primary preventive measure such as; COXII inhibitors, ACE Inhibitors, AIIAs, Statins and Indomethacin.
B.Early intervention through Determine inflammatory markers of early stroke occurrence and determine their diagnostic value to ensue stroke and use recent therapy with appropriate time window as early as possible with follow up of stroke patient clinically and laboratory through markers titre.